John K. Buolamwini, Ph.D.


John K. Buolamwini, Ph. D.

Professor

Office location

847 Monroe Ave Room 327C
Memphis, TN 38163
Tel: (901) 448-7533
Fax: (901) 448-6828
Email: jbuolamwini@uthsc.edu

Current Office Hours

by appointment

CURRICULUM VITAE

EDUCATION AND TRAINING

  • B. Pharm. (Honors), University of Science and Technology, Ghana, 1981
  • M.S. (Pharmaceutical Chemistry), University of Science and Technology, Ghana, 1985
  • Ph.D. (Synthetic Medicinal Chemistry), University of Alberta, Canada, 1990
  • Alberta Cancer Board Fellow: University of Alberta, Canada, 1990-1992
  • NIH Fogarty Fellow: National Cancer Institute, Bethesda, MD, 1992-1994

RESEARCH INTERESTS

Research in Dr. Buolamwini's Laboratory focuses on the design, synthesis, isolation and/or modification and evaluation of new molecules as potential therapeutic agents or pharmacological and biochemical research tools. Approaches used include computer-aided drug design by molecular modeling, 2D- and 3D-QSAR (CoMFA, CATALYST) using state-of-the-art multivariate statistical analyses (PLS) and artificial neural networks, organic synthesis including combichem, antisense oligonucleotides, cell and molecular biology, as well as flow cytometric and radioisotope methods of analysis of ligand-receptor interactions.

CURRENT RESEARCH PROJECTS

  • Design and discovery of nucleoside transporter inhibitors and gene expression regulators for treatment of cancer, heart disease and stroke
  • Design and development of molecular probes for nucleoside transporters
  • Structural biology studies on nucleoside transporters
  • Structure-based design and discovery of novel HIV Integrase inhibitors for AIDS therapy
  • Structure-based design and discovery of inhibitors of p53-MDM2 interaction for cancer therapy
  • Structure-based design and discovery of inhibitors glutathione S-transferase pi (GST-pi) variants for cancer therapy.

EXTERNAL FUNDING SOURCES

  • NIH (National Cancer Institute, National Heart Lung and Blood Institute)
  • American Heart Association
  • American Association of Colleges of Pharmacy
  • American Society of Pharmacognosy

TRAINING OPPORTUNITIES AVAILABLE

  • Postdoctoral Fellowships
  • Graduate Studentships
  • Undergraduate Research Training

PROFESSIONAL SERVICE

  • Editor-in-Chief, Current Cancer Drug Targets, (To be launched 2001)
  • Editorial Advisory Board Member, Current Medicinal Chemistry 1997-Present
  • Executive Guest Editor (Novel Anticancer Drug Discovery Issue), Current Pharmaceutical Design (3/2000)
  • Reviewer: Journal of Medicinal Chemistry
  • Reviewer: Journal of Natural Products
  • Reviewer: Journal of Computer-Aided Molecular Design
  • Reviewer: Biopharmaceutics and Drug Disposition
  • Reviewer: Expert Opinion in Investigational Drugs
  • Reviewer: Journal of Biomolecular Screening
  • Grant review consultant for NIH study section on a special emphasis RFA, 1998
  • Grant review consultant for NIH study section on a special emphasis RFA, 1997
  • Legislative Committee member of the American Association for Cancer Research, 1998-present
  • Grant reviewer for the American Chemical Society Petroleum Research Fund, 1996

PROFESSIONAL SOCIETY MEMBERSHIP

  • American Association for Cancer Research, 1993-Present
  • American Association of Colleges of Pharmacy 1994-Present
  • American Chemical Society 1992-Present
  • American Society of Pharmacognosy 1994-Present
  • International Society for Analytical Cytology 1990-1997
  • Rho Chi Pharmacy National Honor Society 1995-Present.
  • New York Academy of Sciences 1995-1997

INVITED SPEAKER SEMINARS

  1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, Approaches to the Design and Discovery of Novel Agents Against Molecular Targets in Heart Disease, Stroke, Cancer and Aids. May 8, 2000.
  2. Delta State University, Cleveland, MS, Mississippi Alliance for Minority Participation Guest Speaker, November 15, 1999
  3. Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL. Molecular Modeling Approaches to the Design and Discovery of Inhibitors of Nucleoside Transporters or Glutathione S-Transferase Pi Polymorphic Enzymes June 2, 1999.
  4. Department of Chemistry, University of Arkansas at Pine Bluff, Arkansas. Computer-Aided Ligand Design and Molecular Biology Approaches to the Discovery of Novel Agents for the Treatment of Heart Disease, Stroke and Cancer. March 4, 1999.
  5. Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A. & M. University, Tallahassee, Florida. Computer-Aided Ligand Design and Molecular Biology Approaches to the Discovery of Novel Agents for the Treatment of Heart Disease, stroke and Cancer July 16, 1998.
  6. Department of Pharmaceutical Chemistry, College of Pharmacy, Rutgers University, Piscataway, NJ, Application of Computer-Aided Ligand Design and Molecular Biology Approaches to the Discovery of Novel Agents for the Treatment of Heart Disease, Stroke and Cancer June 25, 1998.
  7. Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, Application of Computer-Aided Ligand Design and Molecular Biology Approaches to the Discovery of Novel Agents for the Treatment of Heart Disease, Stroke and Cancer February 18, 1998.
  8. Department of Chemistry, University of Memphis Health Science Center, TN."Computer-Aided Design and Discovery of Nucleoside Transport Inhibitors". October 20, 1995.
  9. Department of Medicinal Chemistry, University of Mississippi, Oxford, U.S.A. "An Integrated Approach To The Discovery of Molecular Targets And Agents For The Therapy of Cancer and AIDS" March 4, 1994
  10. Department of Physiology, University of Alberta, Edmonton, Canada. "Structure-Function Relationships of SAENTA-fluorescein Conjugates: Molecular Modeling Studies" February 8, 1994
  11. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada. "An Integrated Approach To The Discovery of New Molecular Targets And Agents For The Therapy of Cancer and AIDS" February 15, 1994
  12. Departments of Chemistry and Biochemistry, University of Saskachewan, Saskatoon, Canada. "Molecular Modeling Studies of Structure-Property Relationships of SAENTA-fluorescein Conjugates: " February 22, 1994
  13. Department of Pharmacology, University of Alberta, Edmonton Canada "Structure-Function Relationships of SAENTA-fluorescein Conjugates: Molecular Studies" February 28, 1994

RECENT PUBLICATIONS

Zhu Z, Buolamwini JK. Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorg Med Chem. 2008 Apr 1;16(7):3848-65.

Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway. J Biol Chem. 2008 Mar 28;283(13):8624-33.

Gupte A, Buolamwini JK. Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors.
Bioorg Med Chem. 2007 Dec 15;15(24):7726-37.

Lin W, Buolamwini JK. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J Med Chem. 2007 Aug 9;50(16):3906-20.

Zhu Z, Hofmann PA, Buolamwini JK. Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2921-6.

Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem. 2007 Feb 1;15(3):1212-28.

Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev. 2006 Sep;26(5):569-94. Review.

Gupte A, Buolamwini JK, Yadav V, Chu CK, Naguib FN, el Kouni MH. 6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es). Biochem Pharmacol. 2005 Dec 19;71(1-2):69-73.

Buolamwini JK, Kamath S. Molecule-kinase interaction map. Nat Biotechnol. 2005 Nov;23(11):1346; author reply 1346-8. No abstract available.

Kamath SA, Buolamwini JK. Asp746 to glycine change may have a greater influence than Cys751 to serine change in accounting for ligand selectivity between EGFR and HER-2 at the ATP site. J Comput Aided Mol Des. 2005 May;19(5):287-91.

PATENTS AND PATENT APPLICATIONS

  1. Paterson, A. R. P., Cass, C. E., Gati, W. P., Craik, J. D., Robins, M. J., Wiley, J. S., Jamieson, G. P., Sawyer, W. H., Buolamwini, J. K., and McAdam, D. P. Method and Probes for Detecting Nucleoside Transporter and Method for Producing the Probes. U.S. Patent # 5236902, August 17, 1993. Reissued September 22, 1998
  2. Ali-Osman, F., Lopez-Berestein, G., Buolamwini, J. K., Antoun, G. R., Lo, H.-W., Keller, C. and Akande, O. O. Discovery and Targeting of Novel Glutathione-S-transferase-pi (GST-pi) Genes and Gene Products for Diagnosis, Prognosis, and Therapy of Cancer and Other Diseases.US Patent Issued July 2000.
  3. Weinstein, J. N. and Buolamwini, J. K. Restriction Display (RD-PCR) of Differentially Expressed mRNAs. US Patent Filed August, 1998 (Licensed by Gene Logic Inc.)

BOOKS

Buolamwini, J. K. and Adjei, A. A. (Editors): Novel Anti-Cancer Drug Protocols Volume in Series on Methods in Molecular Medicine. Publisher: Humana Press, Totowa, NJ; Publication Date: Spring 2001

Adjei, A. Aand Buolamwini, J. K. (Editors): Strategies for the Discovery and Clinical Testing of Novel Anticancer Drugs Publisher: Elsevier Press, Amsterdam, The Netherlands; Publication Date: Summer 2001

INVITED BOOK CHAPTERS

Buolamwini, J. K. Novel Molecular Targets for Cancer Drug Discovery. In The Molecular Basis of HumanCancer, Editors: William B. Coleman and G. J. Tsongalis (University of North Carolina at Chapel Hill) Publisher: Humana Press. In press

Buolamwini, J. K. Cell Cycle Molecular Targets and Drug DiscoveryInCell Cycle Checkpoints and Cancer, Blagosklonny M. V., Editor

BOOK REVIEW

Buolamwini, J. K.(1995). Reviewof Flow Cytometry (Microscopy Handbooks 29) by M. G. Ormerod, BIOS Scientific Publishers, 1994, for Society of Industrial Microbiologists.

RECENT CONFERENCE ABSTRACTS AND PRESENTATIONS

  1. Buolamwini, J. K. and Francis Ali-Osman. (2000) ADocking Study of the Binding of Thiotepa in the Putative H-Site Pocket of Human Glutathione S-Transferase Pi Allelo-Polymorphs. 91st Annual National Meeting of the American Association for Cancer Research, San Francisco, April. (Abstract)
  2. Buolamwini, J. K. and Francis Ali-Osman (1999). Molecular Modeling Based-Design of Novel Anticancer Therapeutics that Target the Active Sites of Polymorphic GSTP1 Proteins. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Development and Clinical Validation.Washington, D.C.November (Abstract)
  3. Buolamwini, J. K. and Francis Ali-Osman. (1999) Flexible Docking of 4-Hydroxyifosfamide in the Putative H-Site Of Allelo-Polymorphic Human Glutathione-S-Transferase Pi (GST-) Proteins. 90th Annual National Meeting of the American Association for Cancer Research, Philadelphia, PA, April.(Poster)
  4. Buolamwini, J. K. (1999). A Comparative Molecular Field Analysis (CoMFA) QSAR Study of Conformationally Restricted Cinnamyl HIV Integrase Inhibitors. 218 American Chemical Society National Meeting, New Orleans, LA, August (Abstract)
  5. Sindelar, R. D., Avery, M. A. and Buolamwini, J. K. (1999). Computer-Aided Drug Design Education and Training at the University of Mississippi,218 American Chemical Society National Meeting, New Orleans, LA, August. (Symposium)
  6. Tomoko Mineno, J. Bhonsle, J. Woolfrey, Buolamwini, J. K. and M. A. Avery (1999). 3D QSAR Studies of Taxoids and Analogs. 217American Chemical Society National Meeting, Anaheim, CA, March,. (Poster ).
  7. Elledge, J. C., Andrews, A. D. and Buolamwini, J. K. (1999). Screening Antisense Oligonucleotides for the Downregulation of the Expression of the Equilibrative NBMPR-Sensitive Nucleoside Transporter (es). NIH NHLBI Cardiovascular Biomedical Research Program, University of Mississippi School of Pharmacy, Poster Session, August
  8. Weinstein, J. N., Scherf, U., Ross, D. T., Waltham, M., Buolamwini, J. K., Scudiero, D. A., et al., (1999) mRNA and Protein Expression Databases for the Molecular Pharmacology of Cancer: Omics and Bioinformatics. 90h Annual National Meeting of the American Association for Cancer Research, Philadelphia, PA, April 10-April 14. (Podium)
  9. Goldberg, R. M., Mowart, R. B., Sargent, D. J., Cha, S. S., Adjei, A. A. and Buolamwini, J. K. (1998), A Phase II Study of Fazarabine (FAZ) + G-CSF in Previously Untreated Patients with Measurable Metastatic Pancreatic Adenocarcinoma (ACA): A North Central Cancer Treatment Group Study.Annual National Meeting of the American Society for Clinical Oncology Atlanta, GA, May. (Poster)
  10. Ali-Osman, F. and Buolamwini, J. K. (1998). Dynamic Molecular Modeling of Anticancer Agents to Active Sites of Polymorphic GST-Pi Proteins and Rational Design of Inhibitors for Enhanced Cancer Chemotherapy.First International Meeting on the Experimental Therapeutics of Human Cancer, Frederick, MD, June (Podium)
  11. Hood, S. N., Nimrod, A., Walker, L. A. and Buolamwini, J. K. (1998). Expression of Recombinant HIV Integrase in E. Coli for the Discovery of Novel Inhibitors. School of Pharmacy Poster Session, Oxford, MS, September (Poster)
  12. Willis, T. N. and Buolamwini,J. K. (1998). Synthesis of Ribosyl Analog Of Phloridzin As A Potential Sodium Dependent Nucleoside Transport Inhibitor.Biomedical Research Internship Poster Session, School of Pharmacy, University of Mississippi, University, Oxford, MS, July (Poster)
  13. Buolamwini, J. K. (1998), A. Comparative Molecular field analysis study of benzylidene malonitrile tyrphostins as HER2/neu autophosphorylation Inhibitors. 89th Annual Meeting of the American Association for Cancer Research, New Orleans, March (Podium)
  14. Buolamwini, J. K., Akande, O., Antoun, G. and Ali-Osman, F. (1997) Flexible Docking Study of 1-Chloro-2,4-dinitrobenzene (CDNB) Binding at the Putative H-Site of Human Glutathione-S-transferase Pi (GST-p) Polymorphic Proteins. 214th National Meeting of the American Chemical Society,Las Vegas, September (Poster)
  15. Raghavan, K., Parish, D., Khan, M. and Buolamwini, J. K. (1997) Building a Hypothesis for Nucleoside Transport Inhibitors. 214th National Meeting of the American Chemical Society,Las Vegas, September (Podium)
  16. Weinstein, J. N., Myers, T., Li, G., Waltham, M., Buolamwini, J. K., O'Connor, P., Fornace, A. J., Kohn, K. W., Friend, S., Scudiero, D. A., Monks, A. P., Mayo, J. G., Anderson, L., Duncan, K., Johnson, G. S., Grever, M. R., Chabner, B. A., Wittes, R. E., Sausville, E. A. and Paull, K. D. (1996). An Information-Intensive Strategy for Cancer Drug Discovery: Finding Candidate "p53-Inverse Agents. 87th National Meeting of the American Association for Cancer Research, Washington, D.C., April (Poster)
  17. Sindelar, R. D., Buolamwini, J. K., Cleary, J. D., Davis, W. M., Matthews, J. C., Schlenk, D. K., Williamson, J. S. and Ziska, D. S. (1996) Pharmacogenetics and Pharmacoimmunology, A Multi-Departmental, Multiple Instructor Course.American Association of Colleges of Pharmacy National Meeting, Reno, Nevada, July (Poster)
  18. Buolamwini, John K.(1996)A Comparative Molecular Field Analysis (CoMFA) Study of Nucleoside Analog Inhibitors of Es Adenosine Transport. 211th National Meeting of the American Chemical Society,New Orleans, 3/1996 (Poster)
  19. Buolamwini, John K., Belt, Judith A. and Crawford, Charles A. (1996). A Comparative Molecular Field Analysis (CoMFA) Study of Nucleoside Analog Inhibitors of the cif Transporter. 87th Annual Meeting of the American Association for Cancer Research, Washington, D.C., April, (Abstract)
  20. Buolamwini, John K., Weinstein John N. and Paterson, Alan R. P. (1995). Molecular Modeling Studies on SAENTA-Fluorescein Conjugates. 210th National Meeting of the American Chemical Society,Chicago, IL, August (Poster)
  21. Myers, T., Weinstein, J. N., Raghavan, K., Buolamwini, J. K., Anderson, N. L., O'Connor, P., Kohn, K. W., Scudiero, D. A., Monks, A. P., Friend, S. Zaharevitz, D., Rubinstein, L. V. and Paull, K. D. (1995). An "Information-Intensive" Strategy for Drug Discovery in Cancer and AIDS: Relating Cell Cycle Factors to Patterns of Drug Activity. 86th Annual Meeting of the American Association for Cancer Research, Toronto, Canada, March (Podium)
  22. Buolamwini, J. K.,. Raghavan, K., Pommier, Y., Kohn, K.W. and Weinstein, J. N. (1994) Application of the Electrotopological State Index to QSAR Analysis of Flavone Derivatives as HIV-1 Integrase Inhibitors. 208th National Meeting of the American Chemical Society,Washington, D.C.August (Poster)
  23. Buolamwini, J. K., Myers, T. G., Scudiero, D. A., Grever, M. R., Anderson, N. L. and Weinstein, J. N. (1994). Searching forNew Molecular Targets for Therapy of Cancer and AIDS: Characterization by 2D Protein Gel Electrophoresis. 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April (Poster)
  24. Raghavan, K., Buolamwini,J. K., Zaharevitz, D. W., Paull, K.D., Mazumder, A., Fesen, M., Kohn, K.W., Pommier, Y., and Weinstein, J. N. (1994). Finding New Inhibitors of the HIV-1 Integrase: Structure-Based Studies. AIDS Structure Symposium, Bethesda, MD, June (Podium)
  25. Raghavan, K., Buolamwini,J. K., Myers , T., Zaharevitz, D. W., Paull, K.D., Fesen, M., Mazumder, A., Pommier, Y., Kohn, K.W., Grever, M.R. and Weinstein, J. N. (1994). A 3D-QSAR Study of HIV Integrase Inhibitors. 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April (Poster)
  26. Weinstein, J. N., Myers, T., Raghavan, K., Buolamwini, J. K., Anderson, L., Kohn, K. W., Scudiero, D. A., Monks, A. P., Zaharevitz, D., Rubinstein, L. V., Koutsoukos, A. D., Grever, M. R., Chabner, B. A. and Paull, K. D. (1994). An "Information-Intensive" Approach to Drug Discovery for Cancer and AIDS. 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April (Poster)